

Regimen Reference Order – GENU – darolutamide

ARIA: GENU – [darolutamide]

Planned Course: Twice daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Prostate Cancer, Non-metastatic Castration-resistant

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – GENU – darolutamide

Drug	Dose	CCMB Administration Guideline
darolutamide	600 mg	Orally twice daily with food Swallow whole (Self-administered at home)
darolutamide (Nubeqa®) available dosage strength: 300 mg tablet		
Classification: Non-Cytotoxic, Hazardous		

REQUIRED MONITORING

Baseline

- CBC, serum creatinine, liver enzymes, testosterone and PSA as per Physician Orders
- Bone density at physician's discretion

Cycles 2 and 3

- CBC, serum creatinine, liver enzymes, testosterone and PSA as per Physician Orders

Subsequent clinic visits (every 3 months)

- CBC, serum creatinine, liver enzymes, testosterone and PSA as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- darolutamide has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication

ADDITIONAL INFORMATION

- LHRH analog treatment (i.e. leuprolide or goserelin) is continued during darolutamide treatment
- Patients are at increased fracture risk